CTNM Contineum Therapeutics8.20-0.36 (-4.3%)
CTNM Contineum Therapeutics9.26-4.12 (-30.8%)
CTNM Contineum Therapeutics13.04+0.48 (+3.8%)
CTNM Contineum Therapeutics13.35-1.47 (-9.9%)
After Hours Decliner
CTNM Contineum Therapeutics14.820.000.0%
After Hours:14.25-0.57 (-3.9%)
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder
Business WireMon, 14-Sep 4:05 PM
CTNM Contineum Therapeutics16.59-0.98 (-5.6%)